1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBiomedical Catalyst is sponsored by Innovate UK. This program provides grant funding to UK-based small and medium-sized businesses to test and develop innovative health and care solutions across life sciences, including medical devices.
Get alerted about grants like this
Save a search for “Innovate UK” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Biomedical Catalyst – UKRI Area of investment and support Area of investment and support: Biomedical Catalyst This is Innovate UK’s flagship grant funding mechanism helping small and medium-sized businesses test and develop innovative health and care solutions across life sciences, including therapeutics, medical devices, and digital health. The Biomedical Catalyst transforms innovative ideas into commercially viable businesses.
£140 million (over current spending review period) This is an ongoing scheme with multiple funding opportunity rounds The scope and what we're doing The Biomedical Catalyst supports small and medium-sized businesses, of all stages, to: get their project to market quicker de-risk their early stage innovations and projects, and lower risk for investors bring in private capital alongside grants for projects Biomedical Catalyst will fund a variety of projects across different markets, technologies, strands and themes, including: medicines and pharmaceuticals digital health technology Our vision is to build a network of innovative, commercially viable life science businesses that transform healthcare and patients’ lives, and drive business growth.
Opportunities, support and resources available By awarding grants to UK-based businesses at varying stages of development, we enable them to develop innovative healthcare solutions, secure investment and speed up bringing new products to market.
Grants include: Accelerator – Feasibility: opportunity to gain financial support for market and technology feasibility studies Industry-led R&D: transformational grant funding for industry-led innovation projects Investor Partnerships: de-risking innovative technologies by aligning public grant and private enterprise investment We recognise that grant funding alone is not enough, and projects need to be supported as an ecosystem to be able to easily access the partners needed on their innovation journey.
Partners include: Innovation support from Innovate UK Innovate UK Business Connect Innovate UK Business Connect connects innovators with new partners and new opportunities beyond their existing thinking, accelerating ambitious ideas into real-world solutions. If you want help to find a project partner or would like someone to review your application before submission, contact Innovate UK Business Connect .
Innovate UK Business Connect’s health page has information on opportunities, including the Biomedical Catalyst. Innovate UK Business Growth Innovate UK Business Growth offers bespoke advice and support to help grow and scale innovative businesses.
If you’re looking for intensive support with your growth strategy, including exploiting innovation, securing funding and finance, or entering new markets, please contact Innovate UK Business Growth .
Past projects, outcomes and impact Here are some of the many companies supported by the Biomedical Catalyst: Making it easier to capture real-world data in neuroscience studies Learning from nature to identify new antibody-like proteins to treat complex autoimmune diseases A remote monitoring service for cancer patients that restores quality of life Game-changing AI software that helps surgeons be even more precise during brain surgery Screening technology that seeks out new targets to drug the “undruggable” Last updated: 20 June 2025 This is the website for UKRI: our seven research councils, Research England and Innovate UK.
Let us know if you have feedback or would like to help improve our online products and services .
Based on current listing details, eligibility includes: UK-registered SMEs of all stages with evidence of commercial and technical feasibility. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to £500,000 for small projects, over £500,000 up to £2 million total for large projects Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Innovate UK's Sovereign AI Proof of Concept programme funds proof of concept demonstrators of AI technologies with state-of-the-art performance across five strategic themes: fundamental AI research, materials discovery, biosciences and health, defense and national security, and AI-aided chip/hardware design. Individual project grants range from £50,000 to £120,000 (approximately USD $63,500-$152,400) from a total allocation of at least £1.6 million. Projects must be 1-3 months in duration, starting by January 2026 and completing by March 2026. The programme supports feasibility studies and industrial research, with funding covering up to 70% of costs for micro/small businesses, 60% for medium, and 50% for large organizations. Literature review studies and projects unable to scale are excluded.
The Biomedical Catalyst – Industry-led R&D (Small Projects) is a grant from Innovate UK (part of UKRI) that funds the development of innovative solutions to health and healthcare challenges. The programme supports small-scale industry-led R&D projects and is open to both single applicants and collaborative teams. Eligible applicants are UK-registered micro, small, and medium-sized enterprises (SMEs). A total of up to £25 million is available across the competition, with applications closing on 10 December 2025. To lead or work alone on a project, organisations must hold UK SME status and register through the Innovation Funding Service.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.